Matinas BioPharma (MTNB) Reports In-Line Q2 EPS
Matinas BioPharma (NYSE: MTNB) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)